Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the seventh annual global Biopharma Partner Symposium, to be held in Basel, Switzerland on April 2–3, 2020. Genedata customers will present how they use the Genedata Biopharma Platform, discuss new R&D trends and requirements, give input to drive the product roadmap, and network with peers and Genedata experts at the interface between biopharma R&D and IT. Companies attending this invitation-only event include major biopharma R&D organizations Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, GSK, Ipsen, Janssen, Lundbeck, Merck, Novartis, Novo Nordisk, Orion, Pfizer, Roche, Sanofi, Servier, Takeda, and UCB, leading CROs and CMOs Evotec, Novozymes, Octapharma, Sartorius Stedim, and Twist, as well as biotechs Genmab, Immatics, Merus, and Morphosys.
“This is the fourth time I am attending the Genedata symposium and it is great to be part of the quickly growing community and to meet with my peers, who are facing the same kind of R&D challenges,” said Tadas Panavas, Ph.D., Senior Principal Scientist at Boehringer Ingelheim. “The unique thing about the Genedata symposium is the mix of scientific and IT topics, including presentations on exciting new applications—in precision medicine and artificial intelligence, for example—and the more technical topics, such as data privacy, CRO integration, and new cloud and SaaS offerings. This is what makes this symposium distinct and highly attractive.”
Presentations from leading biopharmaceutical companies will focus on innovations in novel therapeutic modalities, such as design of bispecific antibodies, TCRs, CAR-Ts, ADCs, and oligos, MS-based MAM analytical approaches, NGS-based cell line development, biosafety, molecular-based patient profiling, digital pathology, and increasing automation and standardization in biopharmaceutical R&D. In addition, case studies will show how the platform increases process efficiency by allowing real-time investigation of program performance and KPIs, as well as optimization of company-wide resource usage, which reduces costs and improves overall productivity. Participants will have the opportunity to learn and discuss in a precompetitive setting how the Genedata Biopharma Platform can be optimally set up and used to streamline and automate data-rich scientific process and increase efficiency throughout biopharmaceutical research, development, and production.
“Genedata has built the leading platform for digitalizing biopharma R&D over the last 20 years and we are proud that it is being adopted step by step by the majority of leading biopharma companies globally,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Our growing partner community is proof that by bringing our customers to the next level of R&D, we are helping them to develop life-changing therapies faster and better. We are looking forward to meeting all our partners from around the world for another exciting event.”
Editorial Note: The following are among the topics that will be featured at the Genedata Biopharma Partner Symposium:
AstraZeneca: In Vitro Screening and Characterization of Discovery Across Modalities
Boehringer Ingelheim: Evaluation of Next Generation Sequencing (NGS) for Virus Detection & Identification
Pfizer: Using Genedata Software to Improve Biotherapeutic Decisions
Merck: Development of a Digital X-Omics Platform for Clinical Research on Big Biomarker Data
Novartis: Automation of Analytics for Characterization of Biotherapeutics
Novo Nordisk: Fast and Requirement-adapted Multi-attribute Methods (MAM)
Roche: Completing End-to-End Assay Automation with Automated Data Analysis
Sanofi: Platformization of Multi-Specific Protein Engineering
Genmab: Enabling Translational Research with Big Data
Immatics: TCR Development and Deployment of Genedata Software
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.